NuCana plc presented promising data from its Phase 2 NuTide:701 study, showcasing the potential of NUC-7738 in combination with Merck’s Keytruda for treating metastatic melanoma. The combination showed encouraging efficacy signals and a favorable safety profile in patients who had previously failed PD-1 inhibitor therapies.
Exicure, Inc. (XCUR) shares jumped significantly in pre-market trading after regaining Nasdaq compliance. NuCana plc (NCNA) also saw a substantial gain following positive Phase 2 data. However, Rafael Holdings (RFL) experienced a significant drop after a recent surge. This report highlights other notable pre-market movers, including both gainers and losers.
